This page is for Health Care Professionals only
The annual European Crohn’s and Colitis Organisation (ECCO) Congress is the biggest event in the inflammatory bowel disease calendar. The ECCO'22 scientific programme includes a wide range of sessions presented by some of the world’s top specialists, exploring basic science, traditional medicine and clinical practice, as well as a wealth of important new data!
Galapagos is proud to be a sponsor at ECCO'22 and to be delivering an interactive live symposium, as well as a range of other exciting activities throughout the congress. We look forward to meeting you at ECCO'22!
We may be going virtual, but we are still bringing you an unmissable event!
In a series of discursive, case-based presentations, our expert faculty will:
Throughout this event, our speakers will be joined by several special guests. IBD nurse specialist and IBD patient Kay Greveson will share her experiences of living with IBD, while Professor Dotan will bring together several members of her multidisciplinary team, including dietician Dr Lihi Godny and IBD nurse specialist Revital Barkan, to provide their perspectives on how to tackle a challenging patient case.
As well as hearing from this internationally renowned panel, our interactive agenda allows you to guide the discussion by voting for the specialties and topics of most interest to you for the MDT segment.
Don’t miss out! Join us at 18:45 CET on Thursday 17 February 2022 to gain insights from experts and ask them your questions.
This programme is not affiliated with ECCO
Re-treatment with filgotinib in patients with Ulcerative Colitis following treatment interruption: Analysis of the SELECTION and SELECTIONLTE studies
Efficacy and safety of filgotinib in patients with Ulcerative Colitis stratified by age: Post hoc analysis of the phase 2b/3 SELECTION and SELECTIONLTE studies
Efficacy and safety outcomes of long-term treatment with filgotinib 200 mg among patients with Ulcerative Colitis: An interim analysis of SELECTIONLTE
Efficacy and safety of filgotinib for the treatment of perianal fistulizing Crohn’s disease: results from the phase 2 DIVERGENCE 2 study
Filgotinib is currently not approved for Crohn’s disease
Exploring disease control by combining clinical, biological, and health-related quality of life remission with endoscopic improvements among Ulcerative Colitis patients treated with filgotinib: A post-hoc analysis from the SELECTION trial
Indicators for inadequate response among patients with Ulcerative Colitis treated with advanced therapies in German clinical practice
Indicators for inadequate response to advanced therapy in patients with Ulcerative Colitis: results from a medical chart review in the United Kingdom
Rates of clinical remission among patients with Ulcerative Colitis from real-world clinical practice settings from Germany
Insights from patients with Ulcerative Colitis on disease burden: Findings from a real-world survey in Europe
ECCO'22 VIRTUAL CONGRESS!
Join us in the virtual congress from February 16-19, 2022 at 18.45 CET.
Discover the role of the JAK-STAT pathway in UC
GALAPAGOS and the GALAPAGOS logo are registered or pending trademarks of Galapagos
NV.
© 2022 Galapagos NV. All rights reserved.
GL-IBD-NA-202211-00003 12/22
GALAPAGOS and the GALAPAGOS logo are registered or pending trademarks of Galapagos
NV.
© 2022 Galapagos NV. All rights reserved.
GL-IBD-NA-202211-00003 12/22
© Copyright 2022 Galapagos NV
Forgot your PIN? Send an email to omnichannel@glpg.com to retrieve your PIN.
You are about to leave this website and will be redirected to an external website. We are not responsible of that external website’s content. By continuing, you confirm that you have taken note of this.
